TransCode Therapeutics Open Letter to Shareholders
TransCode Therapeutics Open Letter to Shareholders
Many shareholders rightly ask why this request. Some believe that the potential announcement of additional positive clinical data or other good news will favorably impact our stock price. However, there is no assurance that any good news will occur, will occur by the deadline required, or that the stock will rise after any such positive announcement(s). BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Board and Management of TransCode Therapeutics (NASDAQ: RNAZ) today issued the following open letter to shareholders of the Company:
波士頓，2024年11月12日（環球新聞社） - TransCode Therapeutics（納斯達克股票代碼：RNAZ）的董事會和管理層今天向公司股東發出了以下公開信：
Dear Shareholders,
親愛的股東：
At our upcoming Special Meeting to be held November 22, shareholders are being asked to authorize our Board of Directors to effect a reverse split — only if the Board determines that doing so is necessary as described below.
在即將於11月22日舉行的特別會議上，股東被要求授權我們的董事會進行股票的逆向分割 - 僅在董事會確定有必要這樣做且如下所述。
Many shareholders rightly ask why this request. Some believe that the potential announcement of additional positive clinical data or other good news will favorably impact our stock price. However, there is no assurance that any good news will occur, will occur by the deadline required, or that the stock will rise after any such positive announcement(s).
很多股東合理地問爲什麼會有這個請求。一些人認爲，可能會宣佈額外的積極臨床數據或其他利好消息將有利於我們的股價。然而，並不保證會有任何好消息發生，也不保證好消息將在所需的最後期限之前發生，或者股價會在任何這樣的積極消息公佈後上升。
A reverse split is NOT something directors or management wishes to do — we all hope it won't be needed. But the Nasdaq Hearings Panel that approved the extension to continue our Nasdaq listing did so on the condition that our shareholders authorize a reverse split — should one be necessary. The reverse split will not be necessary if our stock closes at $1.00 per share or more for any ten-day period prior to December 31, 2024.
董事會或管理層不希望進行股票的反向分割—我們都希望不會需要這樣做。但納斯達克聽證會批准延長我們的納斯達克上市的前提是，股東授權進行股票的反向分割—如果有必要的話。如果我們的股票在2024年12月31日之前的任何十天期間收盤價達到每股1.00美元或更高，則不需要進行反向分割。
If our stock does not meet this Nasdaq requirement, and we do not have your vote in favor of the reverse split, Nasdaq will delist our stock. A Nasdaq delisting would in all likelihood have a material adverse effect on the value of our company and the value of your stock.
如果我們的股票不符合納斯達克的要求，且沒有您投票支持反向分割，納斯達克將會從納斯達克除牌我們的股票。納斯達克的除牌很可能會對公司價值和您的股票價值產生重大不利影響。
Our assessment boils down to this: your vote is your decision about whether you support our efforts to maintain our Nasdaq listing. Given our need to raise additional capital as soon as possible to continue the clinical trial and other operations, we believe having our stock remain on Nasdaq is critical to raising the needed capital.
我們的評估歸結爲：您的投票決定了您是否支持我們維持納斯達克上市的努力。鑑於我們迫切需要儘快籌集額外資金以繼續臨床試驗和其他運營，我們相信公司股票繼續在納斯達克交易所上市對籌集所需資金至關重要。
TransCode's management and directors are unanimously determined to maintain our Nasdaq listing. This is why we need you to authorize the reverse split, with all of us hoping that we will not have to implement this decision.
TransCode的管理層和董事會一致決定維持我們的納斯達克上市。這就是爲什麼我們需要您批准反向分割，希望我們不必實施這一決定。
We call for your understanding and greatly appreciate your support.
我們呼籲您的理解，並對您的支持表示衷心感謝。
Your Board and Management
董事會和管理層
For more information, please contact:
更多信息，請聯繫:
TransCode Therapeutics, Inc.
Tania Montgomery-Hammon, Business Development
tania.montgomery@transcodetherapeutics.com
TransCode Therapeutics, Inc.
蒂娜·蒙哥馬利-哈蒙，業務發展
該發佈爲「轉讓性訴訟改革法」1995年版中「前瞻性聲明」包含的信息，以下簡稱「本聲明」，包括但不限於有關TransCode Therapeutics股票交易和其他轉讓市場可能發生的事項的陳述。 此類前瞻性聲明均基於公司管理層目前關於未來的預期，受到一些風險和不確定性因素的影響，這些因素可能導致TransCode實際結果與預期結果不同。
譯文內容由第三人軟體翻譯。
